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3Risiko og nytte ved kirurgisk behandling av hjernesvulster – en 
balansekunst
Denne avhandlingen fokuserer på kirurgisk behandling av diffust infiltrerende gliomer som er 
den vanligste formen for primære hjernesvulster. Gliomene inndeles i lavgradige og 
høygradige, hvorav de høygradige er mest aggressive, hurtigvoksende og vanligst 
forekommende. Effekten av kirurgi er omdiskutert for både lavgradige og høygradige 
gliomer. Effektmålene etter svulstkirurgi i hjernen har tradisjonelt vært dødelighet og 
sykelighet relatert til inngrepet, pasientens funksjonsnivå, progresjonsfri overlevelse eller total 
overlevelse. I denne avhandlingen har man forsøkt å belyse effektene av kirurgi på en ny 
måte. 
I den første studien brukte vi Det Norske Kreftregisteret for å se på risiko for død de første 30 
dagene etter operasjon for hjernesvulster, en mye brukt kvalitetsindikator som blant annet 
brukes for å sammenligne kirurgiske teknikker og sykehus med hverandre. Vi fant at denne 
indikatoren trolig er mindre egnet enn ofte antatt på grunn av lav frekvens av hendelser, noe 
som vanskeliggjør meningsfulle statistiske sammenligninger. Den viktigste risikofaktoren for 
tidlig død etter kirurgi er sannsynligvis sykdommens prognose, noe som igjen medfører at 
pasientutvalget, det vil si hvem man opererer, betyr mest for risikoen for perioperativ død. 
De to neste studiene omhandler pasientrapporterte endepunkt, noe som foreløpig er en ganske 
uvanlig som effektmål ved hjernesvulstkirurgi. Vi brukte det enkle spørreskjemaet EuroQol 
5D (EQ-5D) før og etter operasjonen, og fant ut at EQ-5D korrelerer godt med funksjonsnivå
rapportert av helsepersonell. En slik enkel bedømning kan gi et godt og kirurguavhengig bilde 
av forholdet mellom nytte og risiko vurdert av pasientene selv, og et tidlig fall i livskvalitet 
etter operasjon virker å være assosiert med dårligere overlevelse. 
Den siste studien omhandlet kirurgisk behandling av lavgradige gliomer. Den kirurgiske 
tilnærmingen til slike svulster har grunnet mangel på gode studier variert mye mellom sentra, 
og særlig har man sett reservasjon mot kirurgi der svulstene har berørt områder i hjernen som 
man oppfatter som ekstra følsomme (for eksempel i språkområdene). Ved å sammenligne to 
populasjoner som ble håndtert svært ulikt med tanke på kirurgisk tilnærming har vi fått til den 
første kontrollerte studien på kirurgisk behandling av lavgradige gliom. Denne viser at en 
4tilnærming hvor man tidlig fjerner så mye som mulig av svulsten er å foretrekke fremfor kun 
å ta en vevsprøve og vente med kirurgi til fremtidig svulstvekst ses på MR. 
Hovedfunnene i denne avhandlingen er:
- Hjernesvulsters langtidsprognose er en sterk prediktor for død innen 30 dager etter 
kirurgi. Forskjeller i pasientseleksjon, samt den lave forekomsten av perioperativ 
død ved hjernesvulstoperasjoner, er til hinder for pålitelige sammenlignende 
studier. 
- Helserelatert livskvalitet målt med EQ-5D synes å være å være et bra endepunkt i
forskning på pasienter med gliom i hjernen. EQ-5D har sterk korrelasjon til 
tradisjonelle effektmål, men bidrar med pasientsentrert tilnærming og er mer 
nyansert enn tradisjonelle endepunkt. 
- Nevrologiske utfall etter kirurgi har en markant negativ effekt på livskvalitet hos 
pasienter med gliom i hjernen.
- Tidlig reduksjon i livskvalitet etter kirurgi predikerer dårligere overlevelse etter 
kirurgi for den mest høygradige gruppen gliomer (glioblastomer). 
- Tidlig kirurgisk reseksjon gir lengre overlevelse sammenlignet med biopsi og 
påfølgende ekspektans hos pasienter med lavgradige gliom. Initial 
behandlingsstrategi ved lavgradige gliom bør oftest være tidlig kirurgisk reseksjon. 
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5Risks and benefits of brain tumor surgery – a balancing act
The original research presented in this thesis focuses on surgical management of diffuse 
gliomas which are the most common primary tumors within the brain. The gliomas are 
subdivided into low-grade and high-grade, and the latter are most aggressive and most 
prevalent. Both in low-grade and high-grade gliomas the optimal surgical management 
remains controversial. The usual outcome parameters in intracranial tumor surgery have been 
perioperative mortality and morbidity, patients’ functional level, progression free survival, 
and overall survival. In this thesis efforts have been made to illuminate the effects of surgery 
in new ways. 
In the first study we used the Norwegian Cancer Registry to assess the risk of death within 30 
days after surgery for intracranial tumors. This indicator is often used to compare surgical 
techniques and hospital quality. We demonstrated that this indicator is probably of less value 
than often thought due to the low frequency of events which make meaningful statistical 
comparisons difficult. The most important factor for perioperative mortality is the inherent 
prognosis of the disease. This makes the patient selection the most important predictor for 
perioperative mortality.   
In the two next studies we explored patient reported outcomes, a still rather uncommon end-
point in surgical research for intracranial tumors. We used a simple generic questionnaire 
EuroQol 5D (EQ-5D) before and after surgery and demonstrated that EQ-5D is closely 
correlated to functional level as reported by healthcare personnel. Thus, this simple 
assessment gives a good and surgeon independent evaluation of benefit-risk ratio as evaluated 
by patients themselves. In addition, a decline in patient reported health shortly after surgery 
seems associated with impaired survival. 
The last study examined the surgical management in low-grade gliomas. The surgical 
management in these patients has been subject to much debate and management differs 
considerably due to lack of clarifying studies. Lesions involving regions perceived critical for 
neurological function has been particular controversial. By comparing two population based 
cohorts of low-grade gliomas subject to radically different surgical strategy we have achieved 
to produce the first comparative study on surgical management in patients with low-grade 
6gliomas. In this study we demonstrate that initial resection is superior to biopsy and 
subsequent watchful waiting with respect to overall survival. 
This thesis investigated risks and benefits in surgical treatment of brain tumors and the 
following conclusions can be drawn:
- Overall prognosis is a strong predictor of perioperative death. Differences in 
patient selection, and the low incidence of perioperative death in intracranial tumor 
surgery, greatly limit comparative analyses. 
- EQ-5D seems like a good outcome measure in patients with intracranial glioma 
with its strong correlation to traditional variables while being patient centered and 
more nuanced.
- Surgically acquired deficits have a major undesirable effect on quality of life in 
patients with intracranial glioma.
- Early deterioration in quality of life after surgery is associated with impaired 
survival in patients with the most aggressive gliomas (glioblastoma). 
- An initial strategy with resection improves survival as compared to biopsy and 
subsequent watchful waiting. Resection should be the initial treatment option in 
most patients with low-grade gliomas.
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8Errata
In paper IV we erroneously cited the old version of the WHO classification system from 2000 
when we intended to cite the newer version from 2007 which is cited in this thesis (citation 
#1). Also, in paper IV table 1 the percentages representing “men” should in fact be “women”, 
thereby giving the false impression that LGG was more common in women than in men.
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Introduction
Classification of gliomas
Gliomas arise from glial supportive tissue of the brain including astrocytes, oligodendrocytes, 
or ependymal cells.1 The astrocytic tumors represent the majority of the gliomas and the 
World Health Organization (WHO) classifies astrocytomas on the basis of histologic features 
into four prognostic grades:1 grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), 
grade III (anaplastic astrocytoma), and grade IV (glioblastoma). The diffuse LGGs encompass 
diffuse grade II astrocytomas, oligodendrogliomas and oligoastrocytomas (mixed). Pilocytic 
astrocytoma is by definition a LGG, but they are most often looked upon as a separate entity 
due to the non-infiltrating and benign behavior. The diffuse LGGs (WHO grade II) tend to 
recur with time and the histological grading is often more malignant at time of progression. 
The grade III and grade IV tumors are collectively often named HGGs. Thus, it is common to 
consider the diffuse gliomas as a continuum rather than completely separate entities. 
Perhaps as a consequence of being a continuum rather than distinct entities the tissue 
diagnosis of diffuse LGGs and anaplastic astroctytomas is associated with considerable 
interobserver variation.2 Discordant results as high as 60 % was demonstrated for grade II 
astrocytomas, but most were of minor significance from a clinical point of view. Because of 
this it is important to take the necessary precautions to reduce classification bias in research 
on diffuse LGGs. 
Epidemiology of gliomas
The incidence of gliomas is reported to be 6/100,000 persons per year.3 High-grade gliomas
are most common with approximately 5/100,000 persons per year affected with GBMs
accounting for approximately 70 %.4 Low-grade gliomas are less common than HGGs with 
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approximately 0.8 – 1.2/100,000 per year and LGG accounts for 15 % of primary brain 
tumors in adults.5,6 Except for ionizing radiation there are no established correlations between 
environmental factors and the development of gliomas.4
Clinical features and related imaging
Patients with gliomas most often seek medical advice due to alterations of neurological 
functions (i.e. speech, movement, vision and cognition), seizures or due to increased 
intracranial pressure (i.e. headache, vomiting, or affected consciousness). Rarely, although 
increasing with the widespread access to modern neuroimaging, patients receive the diagnosis 
after imaging due to an unrelated condition.
On MRI the HGGs usually present with heterogeneous contrast enhancement in a ring-like 
pattern in T1 images.4 Glioblastomas usually have a central core which is non-enhancing 
representing necrosis as the tumor has outgrown its blood supply and due to microthrombosis 
in tumor vessels. Also, glioblastomas usually present with more peritumoral edema than the 
anaplastic gliomas, a feature best appreciated on MRI in T2-weighted or FLAIR sequences.4
Diffuse LGGs appear hyperintense on T2-weighted or FLAIR MRI sequences, and in contrast 
to HGGs little or no edema is present. Evidence of hemorrhage and calcifications are more 
common in oligodendrogliomas.7 Lesions usually extend along white matter tracts and it is 
not uncommon with growth in corpus callosum and even into the contralateral hemisphere.8,9
Rarely diffuse LGG involves three or more lobes and is then termed gliomatosis cerebri, and 
although histopathologically a grade II tumor the widespread disease is associated with a 
worse prognosis. Contrast enhancement when present is usually patchy and occurs in 15-39 % 
of cases with diffuse LGG.7 Areas of particular interest that could go unnoticed with the use 
of conventional methods only can be detected by metabolic imaging where focal hot spots 
may represent areas of malignant degeneration. Such imaging may be particular important for 
representative sampling within a heterogeneous tumor, that again could lead to a lower 
number of contrast enhancing tumors in the “true” diffuse LGG population.10
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Figure 1
MRI of typical low-grade glioma. To the left is a T2-weighted axial image demonstrating 
hyperintense signal in the left frontal lobe. To the right is the corresponding coronal FLAIR 
image. Contrast enhanced T1-images did not demonstrate any contrast enhancement. The 
patient underwent complete resection of the tumor and the histopathology concluded with 
oligoastrocytoma, WHO grade II. 
The tumors’ anatomical relationship to so-called eloquent brain regions can be suggested 
from preoperative MRI. The term eloquent is somewhat ill-defined, but a common 
interpretation is that sensorimotor regions, language cortices, visual cortex, basal ganglia 
and/or larger white matter tracts represent eloquent regions.11 Since these regions have critical 
role for basic neurological function, the involvement of tumor in these regions often influence 
treatment strategies. To grade the lesions proximity to these regions a classification system 
was proposed by Sawaya et al, and this is perhaps the most common way to grade eloquence 
from an anatomical point-of-view (table 1).12 As seen, grading eloquence even with the use of 
a classification system is subject to interpretation, especially for the intermediate group. 
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Table 1: Grading of eloquence in according the system suggested by Sawaya
Grade 1; non-eloquent brain Grade 2; intermediate Grade 3; eloquent brain
Frontal or temporal polar Near motor or sensory area Motor/sensory area
Right parietooccipital Near visual area Visual area
Cerebellar hemispheric Near speech center Speech center
Near dentate nucleus Internal capsule
Near brain stem Basal ganglia
Hypothalamus/thalamus
Dentate nucleus
Brain stem
Modern neuroimaging with fMRI for identification of cortical functions and DTI to identify 
the course of white matter tracts is increasingly used in planning of brain tumor surgery. 
Using these techniques areas important for movement, vision and language functions can be 
visualized and incorporated into the neuronavigation system for guidance during surgery.4,13
This is a useful technique since it reveals the relationship between the tumor and these critical 
structures. At neurosurgical department, St. Olavs University Hospital we have used a 
strategy combining import of fMRI and DTI data into a navigation system with intraoperative 
3D ultrasound.13 In our experience, the eloquent areas visualized with fMRI and DTI usually 
lie outside the tumor margins visualized by ultrasound in patients without neurological 
deficits. Resections were performed according to these tumor margins in the 3D ultrasound 
images, with particular care in areas neighboring eloquent areas. To correct for the brain shift 
caused by the resection, the 3D ultrasound acquisition was repeated several times during the 
operation. Other commonly used methods for achieving extensive resections while preserving 
neurological functions postoperatively are intraoperative MRI,14 fluorescence (5-ALA),15 and 
the use of various mapping techniques.16,17
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Figure 2
Images from a typical glioblastoma. The images are from the neuronavigation system. The 
preoperative MR images are presented above with corresponding intraoperative ultrasound 
images below (acquisition taken before resection).
For surgical planning and treatment monitoring modern MRI techniques are increasingly 
utilized.3 Perfusion MRI adds information on angiogenesis that again correlates with WHO 
grade, diffusion weighted sequences adds information on cellularity, and tumor metabolism is 
visualized by MR spectroscopy and MR PET using radiolabelled tracers.3,10,18,19
The most common presentation of diffuse LGG is seizures occurring in about 60-80 % of 
patients.8,20 Occasionally patients with LGG are diagnosed when seeking medical advice for 
unrelated conditions and this occurs in about 2-10 % of cases.21,22 However, with the 
increased use of modern neuroimaging this number is expected to increase slightly in the time 
to come. Incidental diffuse LGGs are reported to be smaller and with a better prognosis than 
the symptomatic LGGs,21,22 a finding that may be linked to an earlier diagnosis per se (lead 
time bias). 
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In HGG the clinical presentation may be a true medical emergency with increased intracranial 
pressure leading to impaired consciousness. The mass effect caused by the tumor and its 
surrounding edema can in most cases effectively be relieved with surgery and corticosteroids. 
Prognostic factors
Prognostic factors at time of diagnosis include patient characteristics and findings on 
diagnostic imaging. There have been numerous efforts to divide the patient population into 
different prognostic groups.8,9,23 In the neurosurgical literature the controlled clinical studies, 
both prospective and retrospective, are clearly in minority.24 Therefore, efforts in defining 
prognostic factors are meaningful to researchers in an attempt to adjust for case-mix between 
studies to compare results in a reliable manner. However, clinicians and patients cannot solely 
rely on such indexes when deciding among the therapeutic options since the prognostic 
factors are usually too imprecise for use in individual patients. 
The median survival in patients with diffuse LGG is often reported between 5 to 10 years.7-9 It 
needs to be acknowledged that the survival time clearly depends upon prognostic groups. For 
prediction of survival in diffuse LGGs the Pignatti score is much used.8 Age  40 years, 
diameter  6 cm, tumor crossing midline, neurological deficit, and astrocytoma histology 
constitute the score, and one point is given for each factor present where a higher score 
indicates a worse prognosis. 
The median survival in HGG with modern treatment is reported to be 14 to 15 months in 
randomized trials,25,26 with 2-year survival of 27 % and 5-year survival of 10 %.27 Since 
randomized trials consist of highly selected patients the results from real-life conditions in 
unselected cases differ considerably as median survival is 9.5 months with 2-year survival of 
17 % in population based data.28 For HGGs the established clinical risk-factors are age and 
preoperative clinical condition, often measured with KPS.29,30 A prognostic system, the RPA 
classes, in HGG has been much used which includes tumor grade and treatment related factors 
in addition to the prognostic pretreatment clinical characteristics.27,31-33 The RPA system has
been shown to be more important for prognosis than the subsequent oncological treatment31,34
and is significantly associated with survival also in the modern era.27,33 To adjust for co-
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morbidity the most used score is the Charlson co-morbidity index.23 Although not much 
utilized in neurosurgical research, the scale seems feasible and valid.35-37 The index has
demonstrated predictive capabilities for overall survival in a wide range of patient populations 
including intracerebral hemorrhage38 and ischemic stroke.39 It is also suggested that modern 
metabolic imaging offers prognostic information in patients with gliomas.40
Recently it has been acknowledged that molecular markers add important prognostic 
information. Most important in HGG is the presence of O6-methylguanine-DNA
methyltransferase (MGMT) promoter methylation which predicts response to the 
chemotherapeutic agent temozolomide.27,41,42 In oligodendroglial tumors the combined loss of 
chromosomes 1p/19q represents a favorable subgroup of patients.43,44
Surgical strategy
The growth pattern in gliomas has generally been considered incompatible with the idea of 
achieving total surgical removal of all tumor cells. Several different surgical approaches have 
evolved, perhaps as a consequence of not being able to offer a cure for these patients. In 
example, the range of treatment options in a typical diffuse LGG case is from serial imaging 
(“watchful waiting”) to attempting for early total resection of the tumor. The most common
factors when deciding the surgical strategy include age, co-morbidity and the perceived 
resectability of the tumor. Therefore, patient selection is presumably the key to achieve 
excellent results, and when reading the literature it has to be remembered that uncontrolled 
series have an inherent selection bias, since higher resection grades are often obtained in 
patients with a better prognosis to begin with.
In HGG there is now strong evidence in favor of reaching for radical surgical resection in 
selected patients.26,45 However, the optimal treatment strategy for HGG patients where the 
complete removal of the tumor bulk is not achievable remains controversial. Whether subtotal 
resection offer a clinical meaningful survival benefit remains unclear. The survival benefit of 
an aggressive strategy is likely smaller and risks may perhaps outweigh the potential benefits 
from subtotal debulkings. New deficits and deterioration of HRQL postoperatively seems 
associated with impaired survival,46,47 possibly by enhancing the invasiveness of the 
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remaining tumor cells due to regional hypoxia,48 or due to withholding adjuvant oncological 
treatments in functionally dependent patients.49 Thus, aiming for gross total resection in all 
HGG patients is probably an overly aggressive approach.
In diffuse LGG a review article stated that the only management option supported with strong 
evidence is tissue diagnosis.50 In the years after this review several papers have reported on 
the benefit of extensive resection.6,51,52 However, in diffuse LGG there have been no 
controlled studies providing a higher level of evidence even in recent years – although the 
accumulating surgical series indicate a survival benefit with resection. The consequence of the 
lack of high-quality evidence was exemplified in a recent study on management in LGG 
demonstrating large differences in preferred treatment strategies.53
Adjuvant treatment in diffuse gliomas
Adjuvant therapy, in the form of chemotherapy and radiotherapy, has been extensively 
studied. In the primary management of diffuse LGG the role for either is questioned.6,7
Radiotherapy has been proven to delay progression, but it is not associated with prolonged 
survival.54-56 Thus, deferring radiotherapy until progression to reduce its long term side-
effects57 is common practice. The exact role of chemotherapy in LGG patients is still to be 
defined,6,7 but a recent study has suggested that a regimen consisting of procarbazine, 
lomustine and vincristine (commonly referred to as PCV regime) may have a role in patients 
undergoing subtotal resection.58 Also, specific genetic markers (MGMT promoter methylation
and the combined loss of 1p/19q) may help to better identify a favorable subgroup of patients. 
At our institution it is uncommon to offer chemotherapy as part of the first-line treatment 
unless a very large remnant is left behind or the histology reveals the more aggressive 
gemistocytic astrocytoma.7
In HGG the standard regime consists of temozolomide concomitant to radiotherapy.4,25 At our 
institution a neuro-oncologist assess all patients postoperatively to evaluate if they are 
candidates for radio- and/or chemotherapy. Patients are in practice evaluated for such therapy 
regardless of age, and there is now strong support in favor of offering radiotherapy also to 
elderly with a high functional level.59 Some claim that there is a true multimodal effect 
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between adjuvant treatment and surgical therapy, meaning that the effect of adjuvant therapy 
is particularly good if an extensive resection has been performed.60,61
Evidence is lacking in favor of specific treatments for recurrent tumor,62 but there are now 
several papers on the use of bevacizumab in recurrent tumors claiming modest effects.4,63,64
Addressing the invasion
The diffuse gliomas are characterized by the widespread local invasion by migrating tumor 
cells distant from the gross tumor visible on MRI, by intraoperative 3D ultrasound or in the 
microscope during surgery.48,65-67 It is known that HGG spread along myelinated axons, along 
basement membranes and subependemyma.48 This invasiveness was demonstrated already in 
the early era of brain tumor surgery. In 1928 Walter E. Dandy published a report after 
hemisperectomies in patients presenting with severe neurological deficits, a clinical 
presentation suggesting widespread disease.68 Of the patients surviving surgery, all died of 
recurrent glioma. A biopsy study from 1987 demonstrated infiltrating tumor cells well beyond 
the tumor bulk, and at least as far as the edematous zone on seen on 1.5 T MRI T2 weighted 
images.69 However, despite discouraging results after extensive resections there might be 
some patients with less extensive disease at diagnosis that perhaps could benefit from an 
aggressive surgical approach aiming for super-radical resections.48 In diffuse LGG migrating 
tumor cells have also been identified well beyond the tumor margins as defined by MRI.66
However, in an attempt to halt malignant progression a more refined concept of super-radical 
resection was recently described in a highly selected subgroup, an approach made possible by 
modern imaging. In diffuse LGG located away from eloquent areas super-radical resections, 
as defined by MRI, were guided with functional mapping. Although this was a highly selected 
case-series their seemingly good results are noteworthy.70 Thus, with a targeted patient 
selection and with the guidance of modern surgical tools, there might be a small role for this 
approach in diffuse gliomas also in the future. 
Adjuvant therapies targeting the remaining tumor cells have so far been somewhat
disappointing despite of progress with the use of temozolomide in HGG.25,27 One possible 
explanation for this relative radio- and chemoresistance is perhaps that the migratory cells left 
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behind after surgery are different from cells in the tumor core in that they are not highly 
proliferating.48,71 Thus, some advocate the need for addressing the invasion.48 Recently there 
was a promising report in rats when the migrating glioma cells was targeted with a substance 
called imipramine blue.65 If similar results can be obtained in humans this could represent a 
shift of paradigm and an emerging hope for glioma patients.
Outcome measures in glioma surgery
The traditional studies in patients with primary brain tumors are often focused on disease 
related outcomes (i.e. overall survival, progression-free survival)26,52 and surgically related 
outcomes (i.e. resection grades, new neurologic deficits, complications, and perioperative 
mortality).15,72,73 These measures are invaluable for understanding the impact of surgery, 
improving surgical technique and for understanding the progress in neuro-oncology over time. 
For instance, the surgical mortality may provide information of the surgical technique and the 
pre- and postoperative care, all which are cornerstones in brain tumor surgery. In the era of 
Harvey Cushing the perioperative mortality was often as high as 50 percent, but some 
pioneers were able to demonstrate better results. In Cushing’s personal series of brain tumor 
operations mortality was 13 percent.74 The father of Norwegian neurosurgery and pioneer in 
the field,  Vilhelm Magnus, reported in 1925 a surgical mortality of 10.5 % in the 189 patients 
with brain tumors he had operated in a period of 20-years.75
To measure outcomes from the patients’ point of view, so-called patient reported outcomes 
(PROs), HRQL is much utilized in clinical research. However, in brain tumor surgery the idea 
of measuring PROs is rather new, and much work is still left to be done on this topic.76,77 This 
is perhaps surprising given that surgery is not a curative solution for these patients and quality 
of life should be in focus. Until recently it was common to use one-dimensional scales such as 
KPS (which is not a PRO) to report HRQL, but it is generally accepted that HRQL constitutes 
of several dimensions including physical status, emotional and social well-being.77 There are 
numerous instruments available for measuring HRQL and each have strengths and 
weaknesses, but none developed specifically for assessing the results of brain surgery. 
Generic instruments are usually less sensitive for the specific patient group, but allows for 
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comparison between other groups. Generic instruments are usually simpler which may be of 
benefit in patients having trouble with cognition. Being shorter and simpler the questionnaire 
burden is reduced, thus possibly improving inclusion rates and patient compliance. Even 
though PROs are subjective by nature, HRQL is presumably not unaffected by the traditional 
outcome measures in brain tumor patients, i.e. disease progression or surgical morbidity.46,78
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Aims and Methodological Considerations
The overall aim of this thesis was to study the implications of surgery in patients with primary 
brain tumors.
Paper I
Incidence and causes of perioperative mortality after primary surgery for 
intracranial tumors: a national, population-based study
In this study we used the national cancer registry to study the frequency and possible 
causes of surgical mortality following primary intracranial tumor operations. We also 
sought to explore a possible predictive value of perioperative mortality rates from a 
neurosurgical centre in relation to long-term survival.
Paper II
Quality of life in patients with intracranial gliomas - the impact of modern image 
guided surgery
In this prospective study we aimed to assess changes in HRQL after glioma surgery, to 
explore the relationship between HRQL and traditional outcome parameters, and to 
examine possible predictors of change in HRQL.
Paper III
Postoperative deterioration in health related quality of life as predictor for 
survival in patients with glioblastoma: a prospective study
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In this prospective study the aim was to determine if changes in HRQL was a predictor 
for survival in patients with glioblastoma.
Paper IV
Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy 
Favoring Watchful Waiting in Low-Grade Gliomas
In this retrospective cohort study with parallel group design we studied the impact of 
surgery in a population based quasi-experiment involving two centers with different 
surgical treatment strategies.
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Study populations
The Norwegian Cancer Registry
Study data in Paper I was provided by the Norwegian Cancer Registry. Reports to the 
Norwegian Cancer Registry have been compulsory by law since 1952. Information to the 
registry comes from several independent sources, thus securing a high grade of completeness 
and quality of data. A study from 2001-2005 demonstrated a 93.8% completeness of data in 
all central nervous system tumors, including cases without histological verification.79
Prospective studies 
In papers II and III the included patients were operated for gliomas at the department of 
neurosurgery, Trondheim, Norway in the period from 2007 through 2010. Patients willing to 
participate gave their written informed consent. 
Population based
In paper IV we have population based inclusion from two of the four geographical health 
regions in Norway, North and Mid-Norway. Population based in this context means inclusion 
of all patients receiving a tissue diagnosis of LGG at two university hospitals serving 
exclusively in the health regions with regional referral practice. The inclusion of the cohort 
was retrospective and based on histopathology alone. 
Interobserver variability
In paper IV patients were recruited from two Norwegian university hospitals. In both studies 
inclusion was based on histopathology alone without any exclusion criteria (so-called 
pragmatic design).80 This was a deliberate strategy to maximize external validity by reducing 
assessment bias. However, when dealing with diffuse LGGs a high level of caution is 
necessary since the histopathological diagnosis of diffuse LGGs is associated with 
considerably interobserver variability.2 To confirm diagnoses and rule out classification bias
in comparative analyses it was mandatory to conduct a review of histopathology. Patients 
30
with grade I and II gliomas were identified in the histopathological databases and these 
patients were re-investigated by a neuropathologist from the other hospital for inclusion in the 
study, blinded for the initial diagnosis and clinical characteristics’. Discordant results were 
settled during a meeting between the neuropathologists where consensus was obtained by 
evaluation of the slides in a multi-headed microscope. In total, 47 % of the supratentorial 
tumors screened for inclusion had to be evaluated at the consensus meeting. 
Quasi-experiment
Experimental studies in brain tumor surgery are very rare for several reasons, such as the low 
incidence of tumors, the strong local treatment traditions, patients and surgeons unwillingness 
to randomize between invasive treatments.81 In Paper IV we have had the opportunity to use a 
somewhat unconventional study method. Patients with diffuse LGGs have for several years 
been subject to very different treatment traditions at two adjacent Norwegian university 
hospitals. In retrospect we compared results of the diverging treatment strategies. The centers 
have population based referral eliminating referral bias associated with other referral patterns. 
Norway has a socialized health care system with equal distribution of resources and uniform 
training and licensing of health care personnel. The design with central histopathological 
review ensured uniform inclusion criteria in an unbiased fashion. Thus, our study was a result 
of a natural occurring and practically random experiment where patients were “allocated” to 
treatment based on the residential address. Data collection was done in retrospect making it 
prone to bias, and as a consequence of this we attempted to focus on the hard clinical data less
subject to interpretation by the investigators. The study, being the first controlled surgical 
study in diffuse LGG provides the most convincing evidence to date on surgical decision 
making in diffuse LGG.
Assessment of HRQL
EQ-5D is a generic (not developed for any specific patient group) and preference-weighted 
measure of HRQL.82 There are many different instruments available for measuring HRQL. 
We chose to use EQ-5D in Paper II and III due to the simplicity of the instrument, to enhance 
patient perception and perhaps also compliance. Generic instruments such as EQ-5D lack 
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disease specific questions that may be relevant to the patient group (e.g. cognitive functions). 
Generic instruments may therefore lack sensitivity to measure small benefits or negative 
consequences of surgery. We decided to measure HRQL preoperatively (in most cases after 
the effect of preoperatively administered corticosteroids, if relevant) and 4-6 weeks 
postoperative in an attempt to measure the impact of surgery, and hopefully minimize the 
effect of disease progression or subsequent therapy. 
Assessment of images
Patients in Paper II – III routinely underwent 1.5 T or 3.0 T MRI scans a few days before and 
within 72 hours of surgery. The assessment of tumor volume and resection grades were based 
on these pre- and postoperative MRI investigations using an ellipsoid volume formula 
(4/3Âɥr1r2r3) based on the maximum tumor diameters in the perpendicular dimensions.26 This 
is a crude measure and obviously a simplification compared to the manual segmentation or 
use of semi-automated software systems,83 but we have considered it a reasonable approach in 
this context. In paper 2, an “eloquent location” was defined as cases in which fMRI or DTI 
was used for mapping functional areas. In paper III – IV a validated and more reproducible 
grading system for anatomical eloquence was used.12
Limitations of studies
The main limitations in Paper I is the completeness of reporting and uncertainty of data 
quality in register-based studies. However, analyzing survival is not affected by this data 
quality and the large number of patients reduces impact of possible uncertainty associated 
with single patients. 
Paper II and III were prospective studies with the main focus being exploration of HRQL in 
glioma patients. Since Paper II was the first paper on this topic with the use of EQ-5D we 
explored many potential variables with a high-risk of false-positive findings (type I error). 
The results from this study should therefore be considered hypothesis generating. In addition, 
the high non-compliance may limit the external validity of the findings. In Paper III a less 
explorative approach was used. However, the use of postoperative predictors together with 
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preoperative predictors may treat the preoperative factors with unjust since more information 
is clearly available in the follow-up period. 
The limitation in Paper IV is mainly the retrospective data collection. Also, occasional 
patients, such as elderly with considerable co-morbidity, may have been followed with “wait-
and-scan” without histopathological confirmation, although rarely in both institutions. 
Unfortunately we had no information on resection grades. As we compared different 
treatment strategies another potential bias is the possibility of sampling error in brain tumor 
histopathology. Studies comparing the diagnostic accuracy of biopsy with resection have 
reached conflicting results.84,85 Altogether with histopathological inclusion criteria this is an 
unavoidable drawback and potential criticism to any study comparing resection and biopsy. 
To overcome this challenge a prospective study in suspected low-grade gliomas based on 
radiographic findings would need to be conducted. It may also be argued that the threshold for 
biopsy could differ between institutions and thereby recruiting more patients with worse 
prognosis at one centre. However, in Norway the LGG diagnosed with imaging only is low 
and stable around 0.1/100,000 per year.86 With balanced baseline data and similar incidence 
rates in both geographical regions it seems unlikely that the study findings only reflect 
skewed patient recruitment or the diagnostic accuracies of the two procedures. With respect to 
morbidity that was the secondary end-point, the strategy with regional comparison is not the 
most sensitive for detecting differences.
Ethical considerations
All studies were approved by the Regional Committee for Medical Research Ethics in Health 
Region Mid-Norway.
Paper II and III were prospective and based on informed consent. The need for informed 
consent was waived by the Regional Committee for Medical Research Ethics in Paper I and 
IV. 
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Summary of Papers
Paper I
Incidence and causes of perioperative mortality after primary surgery for intracranial 
tumors: a national, population-based study
Solheim O, Jakola AS, Gulati S, Johannesen TB
Journal of Neurosurgery. 2012;116(4):825-834.
Surgical mortality is a frequent outcome measure in studies of volume-outcome relationships, 
and the Agency for Healthcare Research and Quality has endorsed surgical mortality after 
craniotomies as an Inpatient Quality Indicator. Still, the frequency and causes of 30-day 
mortality after neurosurgical procedures have not been much explored. We sought to study 
the frequency and possible causes of death following primary intracranial tumor operations. 
We also sought to explore a possible predictive value of perioperative mortality rates from 
neurosurgical centers in relation to long-term survival.
Using population-based data from the Norwegian cancer registry we identified 15,918 
primary operations for primary CNS tumors treated in Norway in the period from August 
1955 through December 2008. Patients were followed up until death, emigration, or 
September 2009. Causes of mortality as indicated on death certificates were studied. Factors 
associated with an increased risk of perioperative death were identified.
The overall risk of perioperative death after first-time surgery for primary intracranial tumors 
is currently 2.2% and has decreased over the last decades. An age  70 years and 
histopathological entities with poor long-term prognoses are risk factors. Overlapping lesions 
are also associated with excess risk, indicating that lesion size or multifocality may matter. 
The overall risk of perioperative death is also higher in biopsy cases than in resection cases. 
Perioperative mortality rates of the 4 Norwegian neurosurgical centers were not predictive of 
their respective long-term survival rates.
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Although considered surgically related if they occur within the first 30 days of surgery, most 
early postoperative deaths can happen independent of the handiwork of the operating surgeon 
or anesthesiologist. Overall prognosis of the disease seems to be a strong predictor of 
perioperative death—perhaps not surprisingly since the 30-day mortality rate is merely the 
intonation of the Kaplan-Meier curve. Both referral and treatment policies at a neurosurgical 
center will therefore markedly affect such early outcomes, but early deaths may not 
necessarily reflect overall quality of care or long-term results. The low incidence of 
perioperative death in intracranial tumor surgery also greatly limits the statistical power in 
comparative analyses, such as between published patient series or between centers and 
certainly between surgeons. Therefore we question the value of perioperative mortality rates 
as a quality indicator in modern neurosurgery for tumors.
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Paper II
Quality of life in patients with intracranial gliomas - the impact of modern image guided 
surgery
Jakola AS, Unsgård G, Solheim O
Journal of Neurosurgery. 2011;114(6):1622-1630.
Outcome following brain tumor operations is often assessed by health professionals using 
various gross function scales. However, surprisingly little is known about how modern glioma 
surgery affects quality of life (QOL) as reported by the patients themselves. In the present 
study the authors aimed to assess changes in QOL after glioma surgery, to explore the 
relationship between QOL and traditional outcome parameters, and to examine possible 
predictors of change in QOL.
Eighty-eight patients with glioma were recruited from among those 16 years or older who had 
been admitted to the authors’ department for brain tumor surgery in the period between 
January 2007 and December 2009. A 3D ultrasonography–based navigation system was 
utilized in nearly all operations and functional MR imaging data on eloquent lesions were 
incorporated into the neuronavigation system. Preoperative scores for QOL (EuroQol 5D 
[EQ-5D]) and functional status (Karnofsky Performance Scale [KPS]) were obtained. The 
EQ-5D and KPS scores were subsequently recorded 6 weeks postoperatively, as were 
responses to a structured interview about new deficits and possible complications. 
There was no change in the median EQ-5D indexes following surgery, 0.76 versus 0.75 (p = 
0.419). The EQ-5D index value was significantly correlated with the KPS score (p < 0.001; 
rho = 0.769). The EQ-5D index values and KPS scores improved in 35.2% and 24.1% of 
cases, were equal in 20.5% and 47.2% of cases, and deteriorated in 44.3% and 28.7%, 
respectively. Thus, both improvement and deterioration were underestimated by the KPS 
score as compared with the patient-reported QOL assessment. New motor deficits (p = 0.003), 
new language deficits (p =0.035), new unsteadiness and/or ataxia (p = 0.001), occipital 
lesions (p = 0.019), and no use of ultrasonography for resection control (p = 0.021) were 
independent predictors of worsening QOL in a multivariate model.
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The surgical procedures per se may not significantly alter QOL in the average patient with 
glioma; however, new deficits have a major undesirable effect on QOL. It seems that the 
active use of intraoperative ultrasonography may be associated with a preservation of QOL. 
The EQ-5D seems like a good outcome measure with a strong correlation to traditional 
variables while offering a more detailed description of outcome.
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Paper III
Postoperative deterioration in health related quality of life as predictor for survival in 
patients with glioblastoma: a prospective study
Jakola AS, Gulati S, Weber C, Unsgård G, Solheim O
PLoS ONE. 2011;6(12):e28592.
Studies indicate that acquired deficits negatively affect patients’ self-reported health related 
quality of life (HRQL) and survival, but the impact of HRQL deterioration after surgery on 
survival has not been explored. We aimed to assess if change in HRQL after surgery is a 
predictor for survival in patients with glioblastoma.
Sixty-one patients with glioblastoma were included. The majority of patients (n=56, 91.8 %) 
were operated using a neuronavigation system which utilizes 3D preoperative MRI and 
updated intraoperative 3D ultrasound volumes to guide resection. HRQL was assessed using 
EuroQol 5D (EQ-5D), a generic instrument. HRQL data were collected 1-3 days 
preoperatively and after 6 weeks. The mean change in EQ-5D index was -0.05 (95 % CI -0.15 
– 0.05) 6 weeks after surgery (p=0.285). There were 30 patients (49.2 %) reporting 
deterioration 6 weeks after surgery. In a Cox multivariate survival analysis we evaluated 
deterioration in HRQOL after surgery together with established risk factors (age, preoperative 
condition, radiotherapy, temozolomide and extent of resection).
There were significant independent associations between survival and use of temozolomide 
(HR 0.30, p=0.019), radiotherapy (HR 0.26, p=0.030), and deterioration in HRQL after 
surgery (HR 2.02, p=0.045). Inclusion of surgically acquired deficits in the model did not 
alter the conclusion. 
Early deterioration in HRQL after surgery is independently and markedly associated with 
impaired survival in patients with glioblastoma. Deterioration in patient reported HRQL after 
surgery is a meaningful outcome in surgical neuro-oncology, as the measure reflects both the 
burden of symptoms and treatment hazards and is linked to overall survival.
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Paper IV
Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring 
Watchful Waiting in Low-Grade Gliomas. 
Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, Solheim O. 
JAMA. 2012:Nov 14;308(18):1881-8
There are no controlled studies on surgical treatment of diffuse low-grade gliomas (LGGs), 
and management is controversial.
Objective was to examine survival in population-based parallel cohorts of LGGs from 2 
Norwegian university hospitals with different surgical treatment strategies.
Both neurosurgical departments are exclusive providers in adjacent geographical regions with 
regional referral practices. In hospital A diagnostic biopsies followed by a “wait and scan” 
approach has been favored (biopsy and watchful waiting), while early resections have been 
advocated in hospital B (early resection). Thus, the treatment strategy in individual patients 
has been highly dependent on the patient's residential address. Histopathology specimens 
from all adult patients diagnosed with LGG from 1998 through 2009 underwent a blinded 
histopathological review to ensure uniform classification and inclusion. Follow-up ended 
April 11, 2011. There were 153 patients (66 from the center favoring biopsy and watchful 
waiting and 87 from the center favoring early resection) with diffuse LGGs included.
The prespecified primary end point was overall survival based on regional comparisons 
without adjusting for administered treatment.
Initial biopsy alone was carried out in 47 (71%) patients served by the center favoring biopsy 
and watchful waiting and in 12 (14%) patients served by the center favoring early resection 
(P < .001). Median follow-up was 7.0 years (interquartile range, 4.5-10.9) at the center 
favoring biopsy and watchful waiting and 7.1 years (interquartile range, 4.2-9.9) at the center 
favoring early resection (P = .95). The 2 groups were comparable with respect to baseline 
parameters. Overall survival was significantly better with early surgical resection (P = .01). 
Median survival was 5.9 years (95% CI, 4.5-7.3) with the approach favoring biopsy only 
while median survival was not reached with the approach favoring early resection. Estimated 
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5-year survival was 60% (95% CI, 48%-72%) and 74% (95% CI, 64%-84%) for biopsy and 
watchful waiting and early resection, respectively. In an adjusted multivariable analysis the 
relative hazard ratio was 1.8 (95% CI, 1.1-2.9, P = .03) when treated at the center favoring 
biopsy and watchful waiting.
In conclusion, for patients in Norway with LGG, treatment at a center that favored early 
surgical resection was associated with better overall survival than treatment at a center that 
favored biopsy and watchful waiting. This survival benefit remained after adjusting for 
validated prognostic factors.
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Discussion
Innovations and achievements in surgical treatment of diffuse gliomas
The first reported brain tumor surgery was performed in 1884 by Godlee and Bennett.87 Since 
then, many new concepts have been introduced to benefit the patients with neurosurgical 
conditions in general.74 Cushing performed his first brain tumor operation using monopolar 
electrocautery in 1926, an achievement in close collaboration with its inventor, William 
Bovie.88 Bipolar electrocautery made commercially available by Leonard Malis in 1955,88,89
the appearance of the ultrasonic aspirator in neurosurgery in the late 1970’s90 and the 
emergence of neuronavigation systems have moved the field of glioma surgery forward. 
Further, the introduction of the microscope in a neurosurgical operating theater first described 
in 1957,74 was the fundament for the modern field of microneurosurgery and its many 
advances. With these surgical tools in hand the surgical procedures may be performed more 
targeted, perhaps more radical, but also gentler and safer than before. However, the field has 
continued to be influenced by technical improvements also in the last decades(s). Several 
visualization techniques and functional techniques have moved into the operating room with 
special emphasis on detecting the border between tumor and normal tissue. There are 
promising reports with intraoperative use of 3D ultrasound,67,91,92 intraoperative MRI14,93,94 or 
the use of 5-ALA which makes high grade gliomas visible under fluorescent light.15,26,45,95
The functional border may also be assessed intraoperatively using various sorts of 
mapping.16,17,96,97 It is not a problem to find ambassadors for the use of a certain tool, but in 
what way has this improved care for patients? First of all, brain tumor surgery is much safer 
than it was in the beginning.73,74 Paper I demonstrates that the risk of perioperative death has 
gradually declined the last four decades.73 In glioma surgery important answers concerning 
benefits have been provided in later years. There seems to be a survival advantage when GTR 
is achieved in surgical treatment of glioblastomas.45 Results provided in this thesis also 
significantly strengthen the evidence in support of early and extensive surgery for diffuse 
LGGs.20 Still, the level of evidence in neurosurgery as a field remains poor, and it is necessary 
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to both improve quality of future research and to continue the tradition with technical 
innovation.98
Figure 3
Early postoperative MRI images following resection of an anaplastic glioma (WHO grade 3) 
in the right frontal lobe. The primary operation was performed in 2007 and adjuvant 
radiotherapy and chemotherapy was administered. The patient is doing well (2012) except for
persistent fatigue and some cognitive impairment. 
Improving quality in neurosurgical research
As seen, neurosurgery is a highly technical field where innovations and developments of new 
techniques have been embraced and quickly integrated. There is no doubt that improved 
diagnostics and refinement of surgical tools and techniques have increased safety in brain 
tumor surgery.74 Even though neurosurgery can clearly be performed more safely than before, 
the evidence for performing the operations in the first place can be paradoxically low. This is 
problematic and has contributed to large local variations in practice based on personal 
experience and tradition more than scientific evidence. 
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When evaluating innovative strategies and tools, the neurosurgical researchers have focused 
on case-series rather than randomized controlled trials.24,98 This makes the evaluations prone 
to selection bias and assessment bias and in the end it may be difficult to tell the treatment 
effect from prognostic factors or confounding variables. On the other hand, the surgical 
specialties constantly change with minor adjustments of tools and techniques. Such small 
adjustments are not in isolation expected to contribute to significant differences in outcome.81
The clinical benefit of each new tool to a steadily increasing arsenal of possibilities is no 
longer obvious as perhaps was the situations by some earlier innovations (e.g. the operating 
microscope).99 Since most current improvements are of lesser magnitude a development 
should be reflected in the neurosurgical research by improved scientific methodology, and in 
fact a few methodological high-quality studies were published recently.14,26 It needs to be 
acknowledged that surgical research is different and more complex compared to 
pharmaceutical research, and the conventional randomized trial is not always feasible. There 
may also be situations where only minor modifications are performed to techniques and tools 
may not be proper for testing in time-consuming and costly trials since detection of important 
clinical difference is unlikely. Randomized controlled trials, although desired, is not 
necessarily the solution if clinical equipoise is no longer the case. As experienced in a 
randomized controlled trial assessing neuronaviagtion in glioma surgery, clinical equipoise 
was present in very few patients (16 % of total), seriously threatening external validity.100 Due 
to the inclusion criteria the patient recruitment was consequently very slow and if continuing 
in the same pace would need 11 years to reach the prespecified sample size, a discouraging 
finding presumably leading to the early discontinuation of the trial.100 Despite the best 
intentions the trial is not capable of guiding treatment decisions and in practice neurosurgeons 
discard the results. However, proper randomized trials should be conducted in situations 
where important difference in surgical strategies exist.81 Initiatives to improve methodology
of surgical research and innovation should be acknowledged and supported.99,101-103 In 
example, evaluation of surgical innovation described stepwise as IDEAL101 (Innovation, 
Development, Exploration, Assessment, Long-term) is helpful for recognizing the stages of 
innovation and it provides a useful framework when deciding on the most appropriate study 
design and outcome for the current stage. Another important way to improve quality of 
surgical research would be increased use of prospective designs, reduce bias in outcome 
assessment, and reporting outcome measures in a standardized fashion. 
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Evidence based versus technology driven research
It is often claimed that when several presumably equally good options exist, none of the 
options are actually good and neither is superior to the other. However, to reach such 
conclusions the hypothesis should be subject to rigorous investigation. In diffuse LGG 
patients the surgical options were steadily increasing for decades, each having their advocates. 
And as pointed out by others, a randomized trial seemed unlikely in the future as well, much 
due to the infrequent nature of the disease, the need for long follow-ups in combination with 
strong and diverse local treatment traditions.50,52,104,105 The various tools and techniques 
developed and marketed for the use in diffuse LGG operations includes neurophysiological 
monitoring and various forms of neuronavigation and intraoperative imaging. Paradoxically,
there was limited evidence supporting that diffuse LGG patients benefit from surgery in the 
first place since the common research strategy had been to investigate the results using the 
tool available without comparing strategies or different tools. Within this myriad of strategies 
and tools some of the differences were perhaps of a magnitude that could be clinical 
important? And is there a way to perform a reliable comparative study? This was the situation 
we were dealing with in Paper IV.20 Researchers occupied with diffuse LGG had failed to 
assess efficacy of a certain strategy or procedure against other strategies, making almost every 
strategy being locally considered as established good practice. However, in recent years an 
increasing amount of papers supporting surgical resection were published,6 but  the strength 
of evidence remained equally low since only case-series with different tools were conducted. 
Even though case-series and registries provide information on treatment results and safety, the 
treatment efficacy cannot always be properly assessed in this manner. As a consequence of 
this complete lack of consensus we identified a marked regional difference in treatment 
strategy between two centers in Norway – a difference so large that we considered it a natural 
occurring experiment. With a pragmatic design with histopatholoical inclusion criteria we 
were able to analyze the difference in treatment policy, a conservative statistical approach 
when searching for a difference. With this study we were able to provide the first properly 
controlled surgical study on diffuse LGG, and it now seems clear that the preferred surgical 
strategy should be resection in most cases. However, while the improvement in survival was a 
result of innovations and technical developments, introduction was based on scarce evidence. 
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While only 8% of patients with histologically diagnosed LGGs in Norway underwent 
resections in the 1980s, the percentage has increased to 80% on a National level today 
(source: Norwegian Cancer registry). Modern neuroimaging, neuronavigation and 
intraoperative imaging have facilitated the aggressive surgery seen in many centers today. 
Based on the observation that tumors recurred locally work was done at our institution to 
improve quality of resections. This ultimately led to the development of a 3D ultrasound 
based neuronavigation system that facilitated the aggressive strategy at our institution from 
the late 1990’s.91,106 Fortunately, our data now show that the radical change in surgical 
aggressiveness made possible by this technology has contributed to improved patient 
survival.20,107 This was not obvious when the pioneers in the field promoted the idea and this 
demonstrates how a surgical field may evolve as a consequence of technical innovation. 
It should be acknowledged that some conditions are not optimal for a conventional 
randomized trial, and patients may even be unwilling to undergo randomization for radically 
different interventions in brain tumor surgery.81 However, with good collaboration between 
institutions better studies with higher level is of evidence is achievable, and this should be the 
goal also in a technology driven field like neurosurgery.  
Modernized outcome measures
In this thesis both old and new outcome measures are explored. Perioperative death rate is 
considered a quality indicator and the publications of death rate have traditionally been 
important in neurosurgery.74 In Paper I we examined a national cohort from 1955 through 
2008 with 15,918 primary operations with respect to frequencies and differences in 
perioperative death rate and it relation to long-term outcome. Due to the very infrequent 
occurrence of death within 30 days of intracranial tumor surgery the comparison of 
perioperative death does not seem very meaningful in a modern context.73 However, such 
numbers are still important to acknowledge the risk of an intervention, and it should perhaps 
still be a part of regular work in quality assurance. The main focus in Paper II and III was 
HRQL, a relatively new measure in neurosurgery.46,77,78 PROs were the natural next step in 
neurosurgical research, mainly for two reasons: 1) it’s a trend in medicine to move away from 
paternalistic care to patient-centered care and 2) the clinical benefit of a new intervention and 
46
tool is no longer obvious in terms of hard clinical end-points such as perioperative death rate 
or overall survival. To evaluate changes of an intervention a more sensitive tool was needed, 
and with PROs we are able to do patient-centered research as well.  Even though we reported 
average values using EQ-5D index, the impact for individual patients may naturally differ. 
Also, significant changes, was not established for EQ-5D in this cohort of patients. However, 
it is common to consider 0.07-0.10 to represent a minimal important difference,108-110 and 
determination of the minimal important difference in EQ-5D for brain tumor patients is part 
of our group’s further research strategy. With the use of minimal important difference the 
results of the less intuitive HRQL-scores become more meaningful for clinicians and patients.
Another positive aspect of PROs is its prospective nature, which is a necessary step in the 
right direction for neurosurgical research. To best assess the effect of a procedure a 
preoperative, early postoperative (weeks) and late postoperative (months to years) 
assessments should be done. Patients treated with intracranial tumors at St. Olavs University 
Hospital are now invited to be part of such prospective research on HRQL. To us this is a 
major improvement and clearly a reduction of bias compared to surgeons’ evaluations of own 
results in retrospect which is still a fairly common practice. 
In this thesis we utilized a generic instrument (EQ-5D). Although less sensitive for the 
specific patient group, it still offers the patient perspective in a less biased manner. EQ-5D is 
simple, a feature that may be of benefit in patients with cognitive disturbances. Also, the short 
and simple format reduce questionnaire burden and may improve inclusion rates and patient 
compliance. In addition, being generic it is also possible to compare across diseases. There are 
also disease specific HRQL measures available for patients with brain tumor.  The EORTC 
QLQ-C30 consist of cancer specific questions in addition to assessment of overall health and 
HRQL.111 A brain tumor specific module called EORTC QLQ-BN20 is also available and 
intended for use together with the QLQ-C30. 112 These questionnaires are more sensitive since 
they consist of 50 questions compared to the 5 questions in EQ-5D. They are still not 
developed for the evaluation of neurosurgical interventions, but are developed by oncologists. 
As a consequence the questionnaires focus less on effects of brain surgery, but more on 
known adverse reactions to chemotherapy and radiotherapy. Not to be underestimated in this 
context is the psychological distress of answering 50 questions pre-operatively related to 
cancer and brain tumor in patients without a histopathological diagnosis. Also, the 
questionnaire burden is high if several follow-up assessments are scheduled. The different 
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properties of the generic and disease specific PRO measures should be carefully considered 
when planning a study. In general, the disease specific measures should perhaps be chosen in 
comparative studies since the higher sensitivity makes them better equipped to identify 
between groups differences.
Comparing outcome 
To fairly compare results between centers, regions or countries or study groups, several 
factors need to be considered. The factor probably being most important for achieving good 
results in surgery, and perhaps in every medical discipline, is the selection of patients. This 
was exemplified in a recent study.113 However, outside clinical trials patient selection is 
difficult to control, but clear reporting of eligibility criteria, predictors, follow-up and data 
collection,  as stated in the STROBE statement,114 ensures transparency and this again could 
allow for more just comparisons. In addition, to compare more honestly, at least co-
morbidity23,115 and the clinical condition29 should be adjusted for to prevent the results from 
just reflecting the institutions’ case-mix. 
Unfortunately comparing across studies, to reach self-evident conclusions on the basis of 
case-mix, is not uncommon. Recently a meta-analysis receiving much attention on 
intraoperative stimulation was published. In the pooled analysis of mainly retrospective case 
studies, increased early morbidity rates and lower late morbidity rates were seen when 
intraoperative stimulation was in use, and the authors concluded that intraoperative 
stimulation should be standard of care in glioma surgery.116. However, attempts at scientific 
alchemy by constructing hard evidence from pooling weak evidence are often dubious, as the 
weaknesses are also pooled. Also, there are reasons to argue that the generalization to 
everyday glioma surgery, recommending universal use of intraoperative stimulation mapping, 
is problematic and scientifically unjustified. Low-grade gliomas and HGGs were analyzed 
together in the meta-study. Although biologically related, the disease courses, age groups, 
presenting symptoms, aims of treatment, treatments, surgical results in terms of functional 
outcomes and resection grades, and the use of surgical tools are clearly very different. In 
unselected patients with glioblastoma survival is still only 10 months117 and the impact of 
surgery on survival remains modest even in highly selected patients.26 Any new deficits in 
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patients with HGGs (also early deficits) are clearly negative and should not be compromised 
against extents of resection since early deficits have a direct negative impact on HRQL.78 The 
younger and often highly functional LGG patient may also tolerate a deficit better, equivalent 
to better outcomes in younger patients with traumatic brain injury.118,119 Thus, comparing 
results after intraoperative stimulations in LGGs with results from operations without 
intraoperative stimulations in patients with HGGs, is really like comparing apples and 
oranges. The HGG publications, which were overrepresented in the non-stimulation group,
probably contribute with higher morbidity due to the disease itself and morbidity was indeed 
higher in HGG surgery (6.4% vs 3.4% late deficits). Since the aims of surgery are so different 
in LGG and HGG, outcome should also have been analyzed or reported differently. The 
conclusion of the meta-study may just as well have been: avoid intraoperative stimulation in 
HGGs as it increases the chance of early deficits. 
Another necessary factor for a meaningful comparison of risks and benefits between studies 
or patient groups is the use of standardized outcome measures. The heterogeneity in 
assessment with respect to definitions, timing and length of follow-up precludes reproduction 
and meaningful comparisons of techniques, studies and institutions.  Today’s practice 
assessment of brain tumor surgery includes crude measures in a myriad of different ways. In 
example, even the assessment of perioperative morbidity has until recently not been reported 
in a standardized manner.49,103 From another surgical discipline a review of 107 studies 
identified 56 different definitions of anastomotic leak after gastrointestinal surgery,99,120 and 
there is no reason to believe that the neurosurgical literature is more consistent. There is also 
much potential for both bias and conflicts of interests in the common neurosurgical series 
where the operating surgeon is to rule on whether surgery was a success or not. The recently 
published Ibañez classification103 attempt to introduce a standard way of reporting 
complications in neurosurgery, but researchers in clinical neurosurgery are still lacking a
feasible tool for assessment of severity and frequency of neurological sequelas. As 
demonstrated in this thesis, PROs is a valuable adjunct that may have potential as an outcome 
parameter in brain tumor surgery.46,78 Cognitive assessment,57,121,122 albeit not offering the 
patients’ perspective, offers a more standardized, detailed and perhaps more relevant 
assessment in modern neurosurgery than the traditional outcome measures. 
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Further innovation and refinement
Diffuse gliomas located within regions perceived to contain critical neurological functions 
(eloquent regions) is associated with impaired survival compared to patients with gliomas in 
other regions of the brain.123 This difference is most likely explained by less extensive 
resection in an attempt to avoid surgically acquired deficits.11 In modern neurosurgery various 
tools are available to improve resection and safety. But despite the use of intraoperative 
MRI,14,93 3D ultrasound13,124,125 and intraoperative mapping11,17,116,126 these patients remain a 
challenge. In example, it is not uncommon that patients with gliomas deteriorate in language 
and memory functions postoperatively (i.e. cognitive functions).121,122 These functions may be 
at particular risk if the tumor is involving language areas.121 Thus, further innovation and 
refinement of preoperative assessment together with surgical tools and techniques should be 
encouraged. Also, the combination of techniques may also be beneficial.127,128
Despite the fact that surgery is no cure for diffuse gliomas it is still a very important treatment 
modality both for obtaining tissue diagnosis and for improving survival if safe and radical 
resection are performed. In the short term HRQL is not improved after surgery in the average 
patient with diffuse glioma.78,100 This is perhaps no surprise since little may be gained in 
patients with diffuse LGG having subtle symptoms and in HGG patients the short term gain 
may be modest after the effect of corticosteroids. However, tapering of corticosteroids may be 
possible after surgery – and this may presumably allow patients to maintain their 
perioperative HRQL for a longer period before signs of progression again occur. Even though 
patients as a group did not seem to get short-term benefit from the surgical treatment with 
respect to HRQL it is necessary to emphasize that differences in terms of significant 
subjective changes were not analyzed. It is suggested from our study that about half of the 
patients with glioma remain stable or improve early after surgery.78 In assessment of cognitive 
functions pre- and postoperatively the numbers are quite similar.121,122 This may indicate that 
cognitive problems are strongly correlated with HRQL, perhaps even more so than physical 
symptoms (e.g. a limb paresis).123,129 This may be especially true in LGG patients with time 
for rehabilitation and response shift.77 Despite major technical improvements to date in brain 
tumor surgery patients still experience a high symptom burden and further improvements to 
maximize HRQL is needed. 
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It has to be remembered that safety should remain the primary goal and it should not be 
jeopardized as acquired deficits clearly reduces HRQL78 and an association with impaired 
survival has been reported, at least in HGG.46,47 One theory linking survival with acquired 
deficits is that surgery may lead to vascular damage causing regional hypoxia. This hypoxia in 
relation to the tumor site may induce the remaining tumor cells to migrate leading to increased 
local invasion.48 Our research group is currently investigating the amount of circulatory 
alterations, as defined by diffusion weighted MRI,130,131 occurring after glioma resections and 
the possible association with acquired deficits. Follow-up studies from this work may be able 
to detect possible differences in recurrence patterns or time to recurrence in patients with or 
without MRI detected circulatory alterations. However, it is not only the neurological 
complications that influence outcome. A recent study demonstrated an association between 
complications (not associated with new deficits) and decreased survival, a finding possibly 
related to deferral of postoperative adjuvant treatment.49 This suggests the obvious that a high 
quality of care is needed in all aspects of patient management. 
In the further process of innovation and refinement it is important not only to rely on case-
series without controls. During the late exploration phase of surgical innovation the procedure 
or tool is starting to lose its experimental nature and becoming familiar to many surgeons. For 
conducting an assessment study on efficacy, this has been suggested to be the critical time 
point.99,101,102 Afterwards it will often be widely adopted, and deserved or not, regarded as 
established good practice. However, if missing a step in the innovative hierarchy it is 
important to continue to monitor the effects, either through prospective cohort studies or 
clinical registries. Even though the efficacy of the procedure is better evaluated in controlled 
and preferably randomized studies, the benefit-to-harm ratio of the procedure may be 
monitored in this manner. Also to be emphasized is that slight adjustments of existing 
techniques or tools are probably poor candidates for randomized trials as important clinical 
difference is unlikely.
Primum non nocere
Despite improved safety in brain tumor surgery there is still room for improvement, and it is 
still considered a high-risk field of surgery.132 A recent publication summarizes the main 
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focus areas for prevention of adverse events in intracranial tumor surgery, and they mention 
several strategies including systematic work to reduce deep-vein thrombosis, seizures, and 
infection.132 To reduce surgical related morbidity it is crucial to identify the risks associated 
with surgery in individual patients, but this is not always an easy task. Neurosurgeons have 
perhaps been less focused on the systemic complications of treatment, but rather on 
neurological risks and particularly interest for the tumor’s relationship to certain critical 
regions, a factor being of major importance in clinical decision making. However, anatomical 
eloquence which neurosurgeons have heavily relied on in the past is not reliable enough in 
individual patients.133 With the increased possibilities in modern technologies in preoperative 
planning with fMRI and DTI,13,124,134 intraoperative imaging14,125 and functional mapping17,126
the boundaries have been pushed towards more aggressive surgery without a clear increase in
neurological risks. Even though surgical cure of diffusely infiltrating gliomas is yet to be 
demonstrated, we are now able to remove larger part of the tumor in a safer way, and as stated 
by Kelly in a famous editorial: “we just do not hurt patients as badly as we did 40 years 
ago”.135 However, we would discourage nihilism when caring for these patients since radical 
resection of HGG45 and an aggressive strategy in LGG (Paper IV)20 improves survival, and 
radical resection may act synergistically with adjuvant therapy in HGG.42,60,61
Recommendations for future research
Based on this thesis a few future research recommendations can be made. First, as a field is 
moving forward there is a need for adjusting the outcome measures similarly. As an example, 
comparing institutions on the basis of perioperative mortality after craniotomy seems 
outdated. It may also be advisable to supplement the crude physicians rated outcome 
measures, like KPS, with more detailed and patient centered outcome measures. This would 
provide prospective and less biased research findings. Second, where genuine uncertainty
exists (clinical equipoise) between strategies or tools believed to be clinically important a 
randomized trial should be the default setting for researchers also in neurosurgery. There is 
now an active debate on resection grades “threshold” for achieving survival benefit in patients 
with glioblastoma.45,136-138 Whether or not to perform non-radical debulkings in lesions where 
radical resection is not expected should be subject to a rigid and adequately powered 
randomized controlled trial. Third, a practical tool for assessing neurological function (a 
clinimetric equivalent to the NIH stroke scale for patients with stroke)139 should be accessible 
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for evaluating brain tumor patients. With a reliable and efficient tool that preferably could be 
integrated into clinical practice, researchers would be better equipped to assess perioperative 
neurological function in a standard way and thereby enhance possibilities for comparisons. In 
fact, clinical trials are dependent on a sensitive and reliable outcome measure to detect both 
deterioration and improvement. Together with the Ibãnez classification for complications such 
a tool would also better illuminate the periopeartive risks and benefits associated with brain 
tumor surgery. 
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Conclusions
This thesis investigated the risks and benefits associated with surgical treatment of brain 
tumors and the following conclusions can be drawn:
- Overall tumor prognosis is a strong predictor of perioperative death. The low 
incidence of perioperative death in intracranial tumor surgery limits the statistical 
power in comparative analyses, such as between published patient series or 
between centers and certainly between surgeons. Therefore the value of 
perioperative mortality rates as a quality indicator in modern neurosurgery for 
intracranial tumors may be questioned.
- Surgically acquired deficits have a major undesirable effect on HRQL measured 
with a generic instrument. EQ-5D seems like a good outcome measure with a 
strong correlation to traditional variables while offering a more detailed and less 
biased description of outcome.
- Early deterioration in HRQL after surgery is independently and markedly 
associated with impaired survival in patients with glioblastoma. Deterioration in 
patient reported HRQL after surgery is a meaningful outcome in surgical neuro-
oncology, as the measure reflects both the burden of symptoms and treatment 
hazards and is linked to overall survival.
- Early surgical resection improves survival as compared to biopsy and subsequent 
watchful waiting. Resection should be the initial treatment option in most patients 
with LGG. 
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Abstract
Background: Studies indicate that acquired deficits negatively affect patients’ self-reported health related quality of life
(HRQOL) and survival, but the impact of HRQOL deterioration after surgery on survival has not been explored.
Objective: Assess if change in HRQOL after surgery is a predictor for survival in patients with glioblastoma.
Methods: Sixty-one patients with glioblastoma were included. The majority of patients (n = 56, 91.8%) were operated using
a neuronavigation system which utilizes 3D preoperative MRI and updated intraoperative 3D ultrasound volumes to guide
resection. HRQOL was assessed using EuroQol 5D (EQ-5D), a generic instrument. HRQOL data were collected 1–3 days
preoperatively and after 6 weeks. The mean change in EQ-5D index was 20.05 (95% CI 20.15–0.05) 6 weeks after surgery
(p = 0.285). There were 30 patients (49.2%) reporting deterioration 6 weeks after surgery. In a Cox multivariate survival
analysis we evaluated deterioration in HRQOL after surgery together with established risk factors (age, preoperative
condition, radiotherapy, temozolomide and extent of resection).
Results: There were significant independent associations between survival and use of temozolomide (HR 0.30, p = 0.019),
radiotherapy (HR 0.26, p = 0.030), and deterioration in HRQOL after surgery (HR 2.02, p = 0.045). Inclusion of surgically
acquired deficits in the model did not alter the conclusion.
Conclusion: Early deterioration in HRQOL after surgery is independently and markedly associated with impaired survival in
patients with glioblastoma. Deterioration in patient reported HRQOL after surgery is a meaningful outcome in surgical
neuro-oncology, as the measure reflects both the burden of symptoms and treatment hazards and is linked to overall
survival.
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Introduction
Surgical studies in patients with glioblastoma have focused
much on resection grades and maximal safe resection is usually
advocated. However, measurements of both extents of resection
and safety vary between studies and there are few controlled trials.
Due to non-uniform inclusion criteria and assessments of
outcomes, direct comparison of results and techniques are difficult,
if not impossible [1]. Nevertheless, it seems like resections need to
be extensive to improve survival, but the resection grade threshold
for a probable clinical benefit remains debated [2–4]. Safety is less
often assessed and there is no uniform and accepted method for
reporting of adverse events in surgical trials [5]. Often clinicians or
operating surgeons report clinical outcomes in gross functional
scales with a potential of assessment and interest bias.
The combination of this ultimately fatal disease with the delicate
balance between potential effect and hazards of surgery makes
patients’ perioperative HRQOL of particular interest. However,
the impact of glioblastoma surgery on patient reported outcomes
has not been explored much [6]. We have earlier described
possible predictors of HRQOL in patients undergoing glioma
surgery. The study clearly demonstrated the devastating effect of
acquired deficits on patient reported HRQOL [7]. A recent paper
found that surgical acquired deficits may be associated with
decreased survival as well [8], but the possible impact of
postoperative loss of HRQOL on survival has not been explored.
In the present prospective study we aimed to assess if changes in
HRQOL after surgery added any prognostic information to the
already established risk factors.
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Materials and Methods
Ethics statement
All patients included have given their written and informed
consent. The Data Inspectorate in Norway approved registration
and management of data. The study was approved by the
Regional Ethical Committee for Health Region Mid-Norway.
Methods
Study subjects were recruited from patients aged $18 years
admitted to our department for scheduled brain tumor surgery, in
the period from January 2007 through December 2010. Patients
were followed until death or until May 15th, 2011. Survival was
calculated from the date of surgery. Only patients with
histopathological confirmed glioblastoma according to the WHO
classification were included in this study. Patients provided written
informed consent and filled out the EuroQol 5D (EQ-5D)
questionnaire 1–3 days before surgery. A study nurse scored
preoperative Karnofsky Performance Status (KPS) on admission.
Patient follow-up by a study nurse was scheduled at 6 weeks
(median time to follow up: 47 days) after surgery. We decided to
use 6 weeks to allow for some recovery from transient surgically
induced deficits. In addition, few patients experience significant
tumor progression in this time frame. At this time point some
patients may have started adjuvant therapy and this could
influence the HRQOL, however this is expected to be the same
between the groups and therefore unlikely to influence the results.
Adverse effects are also quite rare during the initiating phase of
adjuvant radiotherapy and/or concomitant temozolomide treat-
ment. Structured interviews were used to assess HRQOL (EQ-5D)
using the same questionnaire as preoperatively. The patients were
also interviewed about possible complications, acquired and/or
worsened deficits (motor, language, vision, unsteadiness and other)
and altered mental functions (memory, personality and other)
experienced after the procedure. Only patients with complete
HRQOL data were included in the analyses. Tumor volumes and
resection grades were determined from preoperative and early
postoperative MRI volumes using an ellipsoid model (4 6r3/3), as
described by others [9]. Gross total resection (GTR) was defined as
no visible contrast enhancing tumor tissue on the early
(,72 hours) postoperative 1.5 T or 3.0 T MRI scans.
Study population
Sixty-seven patients with glioblastoma were included from
baseline, but 6 (9.0%) patients did not complete the EQ-5D
questionnaire after surgery. All patients who did not respond were
dead at last follow-up. Three were lost to follow-up as they were
already dead or in a terminal condition at 6 weeks, whereas the
other three patients who were lost to follow- up lived for a median
30 weeks. The only in-hospital registered complication among
these six patients was seizures in one patient who had no seizures
preoperatively. Median preoperative HRQOL for these six
patients was 0.59 (range 0.27–0.74).
Sixty-one patients had complete EQ-5D forms before and after
surgery and were included in the analyses. Clinical characteristics
are presented in Table 1. The mean age of included patients was
58 years (range 26–81) and 29 (47.5%) were female. The median
preoperative KPS was 80 and 84.7% were functionally indepen-
dent (KPS 70–100). Thirty eight (62.3%) of the operations were
primary and 23 (37.7%) were reoperations.
Surgical procedure
All operations were performed under general anesthesia. The
SonoWandH neuronavigation system was available if requested by
the surgeon and was used in 56 (91.8%) of the operations. The
system utilizes 3D preoperative MRI and updated intraoperative
3D ultrasound volumes to guide resection [10]. In eloquent lesions
functional neuronavigation was incorporated utilizing a method
described in detail earlier [11,12]. Functional MRI and diffusion
tensor imaging data was incorporated into the system in 19
(31.1%) and 23 (37.7%) of the operations respectively. Sixty
(98.4%) of the 61 included patients underwent craniotomy and
tumor resection. One patient underwent biopsy only. The median
preoperative tumor volume was 18.4 cm3 and the median
resection grade was 96.3% with GTR achieved in 24 (39.3%) of
the patients.
The EuroQol 5D
EQ-5D is a generic (not developed for any specific patient
group) and preference-weighted measure of HRQOL [13]. The
questionnaire has been applied to a wide range of health
conditions and treatments as well as population based health
surveys [14,15]. There are many different instruments available
for researchers interested in assessing HRQOL. We chose to use
EQ-5D due to the simplicity of the instrument, to enhance patient
perception and perhaps also compliance. Generic instruments
such as EQ-5D lack disease specific questions that may be relevant
to the patient group (e.g. cognitive functions). Generic instruments
may therefore lack sensitivity to measure small benefits or negative
consequences of surgery. However, we have earlier demonstrated
that EQ-5D shows good correlation to KPS in patients with
gliomas and is responsive to new neurological deficit which is
highly relevant in this patient group. Also, compared to KPS it
offers a more nuanced picture with respect to change after surgery.
Since KPS only measures one physical dimension of HRQOL it is
insensitive to changes in other dimensions [7]. Another important
difference between EQ-5D and KPS is that the latter most often is
reported by the physician whereas the former is a patient reported
outcome. The EQ-5D has been validated in a Norwegian normal
population [16], but so far not in glioma patients. In EQ-5D, five
dimensions of HRQOL are scored; mobility, self-care, usual
activities, pain/discomfort and anxiety/depression with 3 possible
answers to each dimension, i.e ‘no problem’, slight problem’ or
‘major problem’. This results in the 243 different possible health
Table 1. Clinical characteristics of the patient population.
Clinical characteristics No. (%)
Age (mean, range) 58 years (28–81)
Female 29 (47.5)
Preoperative KPSa (median, range) 80 (50–100)
Assumed eloquentb 33 (54.1)
Primary operation 38 (62.3)
Tumor volume (median, range) 18.4 cm3 (1.1–233.5)
Gross total resection 24 (39.3)
Radiotherapy (now or prior) 56 (91.8)
Temozolomide (now or prior) 46 (75.4)
Acquired neurological deficits 23 (37.7)
Complications 15 (24.6)
Complications leading to reoperation 2 (3.3)
aKPS, Karnofsky Performance Status.
bEloquence is here defined as grade II and grade III according to the definition
by Sawaya et al. [37].
doi:10.1371/journal.pone.0028592.t001
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states which are transformed into a single index value based on a
large survey in the UK population [17]. EQ-5D index value is
from 20.594 to 1, where 1 corresponds to perfect health, and 0 to
death. Negative values are considered to be worse than death. To
provide examples a patient scoring 2, 1, 1, 1, and 2 receives a score
of 0.78, while a patient scoring 2, 3, 3, 2 and 2 receives a score of
0.08. A visual analogue scale where patients rate their current
health state on a line ranging from 0–100 (worst to best imaginable
health) forms the second part of the EuroQol questionnaire. In this
study only the index value was assessed.
Statistics
All analyses were done with the PASW statistics, version 18.0.
Statistical significance level was set to P,0.05. Q-Q plots were
used to test for normal distribution of data. Central tendencies are
presented as means if data is normally distributed and as medians
when skewed. When analyzing changes in EQ-5D (e.g. before and
after surgery) paired sample t-test was used. For comparison of
groups with skewed distribution we utilized Mann-Whitney U test.
For binominal data we used Pearson’s chi square test.
In the Cox multivariate survival analysis the variables were
chosen on the basis of current evidence. The most consistent factors
affecting survival in patients with glioblastoma are age [18] and
preoperative functional status, usually evaluated with Karnofsky
Performance Status (KPS) [19,20]. High quality evidence for the
efficacy for adjuvant treatment with radiotherapy and temozolo-
mide in selected patients is now available [21,22]. There is also
growing evidence suggesting that achieving gross total resection
improves survival [2,23]. We performed univariate analyses for
each risk factor and included all in the multivariate model. The Cox
multivariate model included the following variables: Age (linear),
extent of resection (linear), radiation (yes, no), temozolomide (yes,
no), preoperative Karnofsky (linear) and deterioration in patient
reported HRQOL (yes/no). We are aware that use of linear data is
preferable for statistical reasons (no loss of information), but
dichotomizing variables makes clinical interpretation easier,
especially when scores consist of several summarized variables,
making the immediate interpretation of a number less intuitive. For
radiation and temozolomide ‘‘yes’’ indicates that the treatment has
been provided at any time during the course of the disease.
Results
HRQOL evaluated with EQ-5D
The mean preoperative EQ-5D index was 0.67 compared to
0.62 postoperatively. The mean decline of20.05 (95% CI20.15–
0.05) is a non-significant change (p= 0.285). There was a wide
range in the difference (20.96 to 0.87) after surgery. There were
30 patients (49.2%) who reported a deterioration 6 weeks after
surgery while 9 (14.8%) were unchanged and 22 (36.1%) reported
improved HRQOL. Treatment and outcome characteristics
comparing the patients with deterioration in HRQOL with the
others are presented in Table 2. Patients who reported
deterioration in HRQOL had EQ-5D index 0.41 postoperatively
as compared to 0.81 in their counterparts (p,0.001). The group of
patients who experienced a deterioration in HRQOL after surgery
(n = 30) more often had acquired deficits (p = 0.017). There was
also a trend for better HRQOL preoperatively (p = 0.051),
although not statistically significant.
Survival
At the end of follow up 22 patients (36%) were still alive.
Median survival was 64 weeks (95% CI 44–84) and a survival
curve is presented in Figure 1.
In a Cox multivariate survival analysis we evaluated the impact
of the established risk factors together with deterioration in
HRQOL. The results are presented in Table 3 and Figure 2A, 2B
and 2C. There were independent associations between survival
and use of temozolomide (HR 0.30, p= 0.019, Figure 2A),
radiation therapy (HR 0.26, p = 0.030, Figure 2B), and deterio-
ration in HRQOL after surgery (HR 2.02, p = 0.045, Figure 2C).
Patients with deterioration in HRQOL more often died during the
first six months following surgery (TYable 2, p = 0.017). Preoper-
ative KPS or surgical extent of resection did not reach statistical
significance. Using KPS as a dichotomous variable (KPS$70) or
categorical values for extent of resection (gross total, subtotal and
biopsy) did not change the conclusion. Inclusion of surgically
acquired deficits in the model did not alter the conclusion either,
and actually strengthened the association between deterioration in
HRQOL after surgery with overall survival (HR 2.4, p = 0.022).
Since requested in the review process, primary and redo
operations were analyzed separately. Ad-hoc testing verified that
temozolomide and radiation therapy were statistically significant
predictors (p,0.05) when the 38 primary operations were
analyzed separately. Deterioration in HRQOL did not reach
statistical significance (HR 2.9, p= 0.05). No statistically significant
predictor was found when analyzing the 23 reoperations
separately.
Discussion
In this prospective follow-up study of 61 glioblastoma patients
we found that deterioration in HRQOL early after surgery seems
to be an independent negative prognostic factor for survival.
Deterioration in HRQOL occurs in about half of the patients
despite the use of modern image guided surgery. The effect of
deteriorating HRQOL was independent of the established risk
factors, such as age, extent of resection, preoperative functional
status (KPS), and adjuvant treatment. The difference in survival
appears to be due to a difference in early mortality. A decline in
HRQOL in the early postoperative phase may be suggestive a
rapidly growing lesion or perhaps negative effects from surgery. It
has been reported that acquired deficits can be associated with
both suboptimal adjuvant therapy [5] and reduced survival [8].
Still, we found that the negative impact of lost HRQOL remained
significant after adjustment for reported acquired neurologic
deficits. Our findings indicate that evaluation of the patients’
perception of own health may be of high prognostic value. If so,
this may allow for new and interesting outcome measures in
glioblastoma surgery that reflect the biology of the disease, the tolls
and the benefits from surgery, while maintaining the relevance for
overall survival. HRQOL measures allow for comparisons across
studies and techniques while avoiding the potential bias associated
with surgeons’ evaluation of own results.
Overall survival is considered the gold standard when
evaluating treatment of glioblastoma and its role is indisputable.
However as survival benefits from surgery can be modest, survival
as study end-point may require multicentre inclusion and years of
recruitment to avoid a statistical power shortage, as experienced in
the 5-ALA study [9]. Further, this measure can be quite unspecific
in a surgical setting as it reflects the results from non-surgical
interventions as well. Progression free survival (PFS) may be used
instead as in the 5-ALA-study [9], but the definitions vary and
interpretation is problematic [24]. Pseudoprogression occurs in
approximately 20% and this makes a pure imaging based outcome
unreliable [25]. There may be contrast enhancement due to the
treatment itself which can be impossible to distinguish from
recurrent disease [24]. Another problem is pseudoresponses, seen
Survival after Postoperative Loss of Health
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with antiangiogenic agents where the disappearance of contrast
enhancement is not necessarily related a clinical response [24,26].
However, the dynamics of tumor progression, the speed of growth,
and patterns of growth may be of prognostic importance if a
reliable measure becomes available.
Extensive resections are advocated by numerous studies due to
the association with improved survival. The association seems
logical, but it is difficult to differentiate the efficacy of treatments
from treatment selection as most studies are neither randomized,
controlled nor prospective [4,23,27]. As mentioned earlier,
differences in patient selection are obstacles for meaningful
comparisons between institutions and techniques. Lastly, with
the exception of the 5-ALA study [9] most studies are not even
designed to evaluate the efficacy of surgical treatment. The present
study does not indicate that extensive resection negatively affects
HRQOL in itself, but it indicates that there is serious potential for
harm in surgical treatment of glioblastomas. We believe careful
therapeutic considerations should be made in cases where safe
gross total resection seems unlikely as the risk might outweigh the
benefit.
These common end-points all have drawbacks which can be
problematic for meaningful clinical interpretation. Since the
prognosis with respect to survival remains unfavorable despite
maximal therapeutic efforts, measuring patients’ quality of survival
is an important supplement [6]. We believe HRQOL adds useful
information both for clinical use and research. Met with the
individual patients, neurosurgeons should take into account the
potential hazards of surgery on patients’ HRQOL and carefully
weigh this up against the likelihood of a survival benefit. Perhaps
the patients’ subjective HRQOL reflects the dynamics of their
disease of prognostic importance, although difficult to quantify
even in serial MRI scans. HRQOL reflects both the burden of
treatment and the severity of the disease and together with the
association to overall we believe that deterioration in HRQOL, or
deterioration free survival after surgery, can be a meaningful
endpoint in surgical trials in neuro-oncology.
In demonstrating prognostic potential of self reported HRQOL
we are in line with earlier studies [28–31]. However, we are not
aware of any other study assessing the prognostic effect of
HRQOL where baseline scores are collected preoperatively.
Other neuro-oncological studies evaluating HRQOL and survival
are usually in the setting of medical clinical trials using initiation of
chemotherapy or radiotherapy as baseline [29–32]. This neglects
Table 2. Comparisons of treatment related factors and outcome among patients experiencing deterioration in HRQOL after
surgery with patients with equal or better HRQOL after surgery.a
Deterioration in HRQOL
(n=30) Equal or improved HRQOL (n=31) P-value
Primary operationb 17 (56.6%) 21 (67.7%) 0.375
KPS (median) preopc 80 90 0.586
Tumor volume (median)c 24.1 cm3 15.9 cm3 0.322
Extent of resection (median)c 95.1% 96.5% 0.715
Gross total resectionb 11 (36.7%) 13 (41.2%) 0.532
Complicationb 8 (26.7%) 7 (22.6%) 0.401
New/worse deficitb 16 (53.3%) 7 (22.6%) 0.017
EQ-5D index (mean) preopd 0.75 0.59 0.051
EQ-5D index (mean) postopd 0.41 0.81 ,0.001
Deaths in month 0–6b 11 (36.7%) 3 (9.7%) 0.012
Deaths in month 7–12b 6 (20.0%) 5 (16.1%) 0.694
Deaths .12 monthsb 6 (20.0%) 8 (25.8%) 0.590
Total deaths in follow upb 23 (76.7%) 16 (51.6%) 0.042
aHRQOL, health related quality of life; KPS, Karnofsky Performance Status; p,0.05 is considered significant.
bPearson chi-square.
cMann-Whitney U test.
dIndependent sample t-test.
doi:10.1371/journal.pone.0028592.t002
Figure 1. Overall survival in the cohort (n =61) presented in a
survival plot.
doi:10.1371/journal.pone.0028592.g001
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the potential effect and hazards of surgery which undoubtedly is
the most invasive form of treatment in patients with glioblastoma.
Patients may perceive their health and HRQOL differently with
regards to sex, tumor location and histopathology [6,7]. Therefore
it is difficult to find an optimal cut-off-value with clinical
significance, and searching for a so called ‘‘best cut-off’’ may be
somewhat dubious and increase the risk for false positive findings
[33]. Utilizing changes instead of absolute values seems clinically
more useful in individual patients. This approach takes individual
differences into consideration as patients are their own controls.
This approach may reduce the problems mentioned above.
However, interpreting changes in HRQOL is not necessarily
straightforward. Changes should be evaluated as clinically
meaningful rather than simply statistically significant. This can
be achieved by anchoring HRQOL to therapy, changes with
disease progression or life events [34].
EQ-5D, a generic HRQOL measure, shows good correlation
with traditional outcome measures [7], and in this study it also
demonstrates an association with hard clinical end-points. Thus it
is seemingly a valuable tool in assessing HRQOL in patients with
glioblastoma. Despite potential shortcomings of generic instru-
ments, we are convinced that patient related outcomes with a
validated questionnaire are interesting, valuable, and perhaps less
biased adjuncts to traditional physician rated outcome measures.
The use of EQ-5D for the entire glioblastoma patient population
should be subject of further studies i.e. defining minimal important
change or measuring HRQOL at multiple time points to better
understand the HRQOL throughout the course of the disease.
However, we would insist on using a preoperative evaluation as
baseline to avoid loss of important information.
The relative high number of complications and acquired deficits
in our patients are most likely explained by the assessment method
used. All adverse events were patient reported, including
uncommon outcome parameters used in the neurosurgical
literature, namely memory difficulties, unsteadiness and personal-
ity changes. When using a more common method of assessment
we have reported complications in 21% and deteriorated
functional outcome in 13% in a consecutive, unselected series in
patients with high grade gliomas [1]. Comparing adverse events
between studies is difficult due to different inclusion criteria and
the lack of a standardized way of reporting [5]. With this in mind
we believe these findings are comparable to a large study where
34% of patients experienced perioperative complications and
9.9% displayed worsened neurological status within 3 weeks after
primary craniotomy for malignant glioma [35]. For the future we
would encourage researches to use one standard way of reporting
since this would facilitate meaningful comparisons, i.e. using the
system for neurosurgical patients recently described [36].
Our study has several limitations. The patients included
represent an unsystematic selection that may not be representative
for the entire population of patients with glioblastoma. We believe
the lost-to follow-up rate of 9% is low. How these lost-to-follow-
Figure 2. Survival curves for the independent predictors presented in Table 3.
doi:10.1371/journal.pone.0028592.g002
Table 3. Cox multivariate regression.a
HR univariate P-value
HR
Multivariate P-value 95% CI for multivariate HR
Lower Upper
Age 1.04 0.023 1.00 0.990 0.97 1.03
EOR 0.99 0.176 0.99 0.403 0.97 1.00
Radiotherapy 0.12 ,0.001 0.26 0.030 0.08 0.88
Temozolomide 0.20 ,0.001 0.30 0.019 0.11 0.82
KPS preoperative 0.98 0.083 0.99 0.325 0.96 1.01
HRQOL deterioration 2.11 0.022 2.02 0.045 1.02 4.00
All variables included in the model are presented both for univariate and multivariate analyses. Radiotherapy, use of temozolomide and deterioration in quality of life 6
weeks after surgery were independently associated with overall survival.
aEOR, extent of resection; KPS, Karnofsky Performance Status; HRQOL, health related quality of life; HR, hazard ratio; CI, confidence interval; p,0.05 is considered
significant.
doi:10.1371/journal.pone.0028592.t003
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ups would have affected the results remains speculative, but as
three were dead or in a terminal condition, it is reasonable to
believe their HRQOL had deteriorated as well and further
strengthened the association. Adjuvant treatment (yes/no) was
included in the Cox regression model in spite of the risk of
survivorship effect overestimating the actual effect of the
intervention. A case-mix with 37.7% reoperated patients where
most had already received adjuvant treatment could possibly lead
to underestimation of the effect of adjuvant treatment. Although
the effect of lost HRQOL seems independent of given adjuvant
treatment, details of treatment protocols were not studied. We
therefore advise to interpret the effects of adjuvant therapy in this
study with some caution. Results from the ad-hoc analyses for
primary operations and reoperations separately, as requested in
the review process, may likely be due to type II errors and should
not alter the interpretation of the study. They suggest that the
findings in this study may be more representative for primary
operations than for reoperations, but this finding needs to be
verified in a larger study. Finally, the statistical method used in
creating a dichotomous variable (worse HRQOL: yes/no) from a
single variable is associated with an increase in false positive
findings [33]. However the cut-off chosen is not created on the
basis of finding the ‘‘optimal’’ cut-off, but out of logic and what we
thought would be of clinical relevance. Another important
statistical culprit is the floor-ceiling effect since patients in a good
preoperative condition can only become worse and vice versa.
Conclusion
Balancing risks with potential survival benefit and clinical
improvement is the key in surgical treatment of patients with
glioblastoma. Resection grades, overall survival, and PFS are
much used outcome parameters in surgical research, but they offer
no information on quality of survival. In this study we have
demonstrated that early deterioration in HRQOL after surgery is
independently and markedly associated with impaired survival.
Deterioration in patient reported HRQOL after surgery is a
meaningful outcome in surgical neuro-oncology as HRQOL
reflects the burden of symptoms, the treatment hazards and is
linked to survival.
Author Contributions
Conceived and designed the experiments: ASJ SG GU OS. Analyzed the
data: ASJ SG CW OS. Contributed reagents/materials/analysis tools: ASJ
SG CW GU OS. Wrote the paper: ASJ SG CW GU OS.
References
1. Solheim O, Selbekk T, Jakola AS, Unsga˚rd G (2010) Ultrasound-guided
operations in unselected high-grade gliomas—overall results, impact of image
quality and patient selection. Acta Neurochirurgica. pp 1–14.
2. Stummer W, Reulen H-J, Meinel T, Pichlmeier U, Schumacher W, et al. (2008)
Extent of Resection and Survival in Glioblastoma Multiforme: Identification of
and Adjustment for Bias. Neurosurgery 62: 564–576.
3. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, et al. (2001) A
multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of Neurosurgery 95: 190–198.
4. Sanai N, Polley M-Y, McDermott MW, Parsa AT, Berger MS (2011) An extent
of resection threshold for newly diagnosed glioblastomas. Journal of Neurosur-
gery 0: 1–6.
5. Gulati S, Jakola AS, Nerland US, Weber C, Solheim O (2011) The risk of
getting worse: Surgically acquired deficits, perioperative complications and
functional outcomes after primary resection of glioblastoma. World Neurosur-
gery In press.
6. Cheng J-x, Zhang X, Liu B-L (2009) Health-related quality of life in patients
with high-grade glioma. Neuro Oncol 11: 41–50.
7. Jakola AS, Unsga˚rd G, Solheim O (2011) Quality of life in patients with
intracranial gliomas: the impact of modern image-guided surgery. Journal of
Neurosurgery 0: 1–9.
8. McGirt MJ, Mukherjee DM, Chaichana KL, Than KD, Weingart JD, et al. (2009)
Association of Surgically Acquired Motor And Language Deficits on Overall
Survival After Resection of Glioblastoma Multiforme. Neurosurgery 65: 463–470.
9. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, et al. (2006)
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The
Lancet Oncology 7: 392–401.
10. Unsgaard G, Rygh OM, Selbekk T, Mu¨ller TB, Kolstad F, et al. (2006) Intra-
operative 3D ultrasound in neurosurgery. Acta Neurochirurgica 148: 235–253.
11. Gulati S, Berntsen EM, Solheim O, Kvistad KA, Ha˚berg A, et al. (2009)
Surgical Resection of High-grade Gliomas in Eloquent Regions Guided by
Blood Oxygenation Level Dependent Functional Magnetic Resonance Imaging,
Diffusion Tensor Tractography, and Intraoperative Navigated 3D Ultrasound.
Minim Invasive Neurosurg 52: 17–24.
12. Rasmussen IA, Lindseth F, Rygh OM, Berntsen EM, Selbekk T, et al. (2007)
Functional neuronavigation combined with intra-operative 3D ultrasound:
Initial experiences during surgical resections close to eloquent brain areas and
future directions in automatic brain shift compensation of preoperative data.
Acta Neurochirurgica 149: 365–378.
13. The EuroQol Group (1990) EuroQol - a new facility for the measurement of
health-related quality of life. Health Policy 16: 199–208.
14. Rabin R, Charro Fd (2001) EQ-5D: a measure of health status from the
EuroQol Group. Annals of Medicine 33: 337–343.
15. Burstro¨m K, Johannesson M, Diderichsen F (2001) Swedish population health-
related quality of life results using the EQ-5D. Quality of Life Research 10:
621–635.
16. Nord E (1991) EuroQol: health-related quality of life measurement.
Valuations of health states by the general public in Norway. Health Policy 18:
25–36.
17. Dolan PD (1997) Modeling Valuations for EuroQol Health States. Medical Care
35: 1095–1108.
18. Lutterbach J, Bartelt S, Momm F, Becker G, Frommhold H, et al. (2005) Is older
age associated with a worse prognosis due to different patterns of care? Cancer
103: 1234–1244.
19. Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, et al. (2011)
Surgical outcomes for older patients with glioblastoma multiforme: preoperative
factors associated with decreased survival. Journal of Neurosurgery 114:
587–594.
20. Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, et al. (2011)
Treatment outcomes for patients with glioblastoma multiforme and a low
Karnofsky Performance Scale score on presentation to a tertiary care institution.
Journal of Neurosurgery 0: 1–10.
21. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.
N Engl J Med 352: 987–996.
22. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, et al.
(2007) Radiotherapy for Glioblastoma in the Elderly. N Engl J Med 356:
1527–1535.
23. Sanai N, Berger MS (2008) Glioma Extent of Resection and its Impact on
Patient Outcome. Neurosurgery 62: 753–766.
24. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al.
(2010) Updated Response Assessment Criteria for High-Grade Gliomas:
Response Assessment in Neuro-Oncology Working Group. Journal of Clinical
Oncology 28: 1963–1972.
25. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical
features, mechanisms, and management of pseudoprogression in malignant
gliomas. The Lancet Oncology 9: 453–461.
26. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, et al. (2011)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North
American Brain Tumor Consortium Study. Journal of Clinical Oncology.
27. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, et al. (2009)
Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of Neurosurgery 110: 156–162.
28. Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The Prognostic
Significance of Patient-Reported Outcomes in Cancer Clinical Trials. Journal of
Clinical Oncology 26: 1355–1363.
29. Brown P, Ballman K, Rummans T, Maurer M, Sloan J, et al. (2006) Prospective
Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas.
Journal of Neuro-Oncology 76: 283–291.
30. Brown PDMD, Maurer MJMS, Rummans TAMD, Pollock BEMD,
Ballman KVPD, et al. (2005) A Prospective Study of Quality of Life in Adults
with Newly Diagnosed High-grade Gliomas: The Impact of the Extent of
Resection on Quality of Life and Survival. Neurosurgery 57: 495–504.
31. Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, et al. (2009)
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of
individual patient data from EORTC clinical trials. The Lancet Oncology 10:
865–871.
32. Mauer M, Stupp R, Taphoorn MJB, Coens C, Osoba D, et al. (2007) The
prognostic value of health-related quality-of-life data in predicting survival in
Survival after Postoperative Loss of Health
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28592
glioblastoma cancer patients: results from an international randomised phase III
EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical
Trials Group study. Br J Cancer 97: 302–307.
33. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of Using
‘‘Optimal’’ Cutpoints in the Evaluation of Prognostic Factors. Journal of the
National Cancer Institute 86: 829–835.
34. Lydick E, Epstein RS (1993) Interpretation of quality of life changes. Quality of
Life Research 2: 221–226.
35. Chang SM, Parney IF, McDermott M, Barker FG, 2nd, Schmidt MH, et al.
(2003) Perioperative complications and neurological outcomes of first and
second craniotomies among patients enrolled in the Glioma Outcome Project.
J Neurosurg 98: 1175–1181.
36. Iban˜ez FAL, Hem S, Ajler P, Vecchi E, Ciraolo C, et al. (2011) A New
Classification of Complications in Neurosurgery. World Neurosurgery 75:
709–715.
37. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, et al. (1998)
Neurosurgical Outcomes in a Modern Series of 400 Craniotomies for Treatment
of Parenchymal Tumors. Neurosurgery 42: 1044–1055.
Survival after Postoperative Loss of Health
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28592

Paper IV
 
Is not included due to copyright 


